In general, ischemia and reperfusion are main causes for tissue damage and consequently for organ damage after surgery. Particularily, patients suffering from a peripheral occlusive disease show a diminished capacity to maintain microcirculation. Peripheral bypass surgery is one option to resue critical limbs from amputation. Therefore, this group of patients most likely would benefit from an early improvement of local blood flow possibly provided through administration of L-arginine.
Conditions
Interventions
Trade Name: L-Arginin-hydrochlorid-einmolar Fresenius
Product Name: L-Arginine hydrochloride
Product Code: L-Arginine
Pharmaceutical Form: Intravenous infusion
Pharmaceutical form of the placebo: Intr
Sponsors
Medical University of Vienna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) female or male patients receiving peripheral bypass surgery 2) age between 55 and 75 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: metabolic acidosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: In this study it should be tested whether an infusion of L-arginine starting at the beginning of surgery and lasting 24 hours would improve local blood flow of patients receiving peripheral bypass surgery.;Secondary Objective: ;Primary end point(s): Local perfusion measured using Laser Doppler flowmetry as well as the temperature gradient between elbow and finger-tip. | — |
Countries
Austria
Outcome results
None listed